Black Titan (BTTC) AI Stock Analysis

• Market Cap: $4.94M
• Dividend Yield: N/A
• Average Volume (3M): 508.16K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.06
• Revenue Growth: -100.00%
• EPS Growth: 54.46%
• Country: US
• Employees: 2
• Sector: Technology
• Sector Strength: 88
• Industry: Asset Management
• EPS (TTM): N/A
• Shares Outstanding: 1,330,234
• 10 Day Avg. Volume: 493,518
• 30 Day Avg. Volume: 508,156
• PEG Ratio: 0.17
• Price to Book (P/B): 1.49
• Price to Sales (P/S): 15.10
• P/FCF Ratio: -91.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 34 Underperform
• Price Target: ―

Titan Pharmaceuticals' stock faces considerable financial performance issues, with declining revenues, negative cash flows, and operational inefficiencies posing significant challenges. Technical analysis indicates a lack of clear momentum, while valuation metrics are unattractive due to negative earnings. The lack of recent earnings call data or relevant corporate events leaves these negative factors largely unchecked, resulting in a low overall stock score.

Black Titan Business Overview & Revenue Model

Company Description

Black Titan Corp. was formed for the purpose of effecting a merger between Titan Pharmaceuticals Inc. and TalenTec Sdn Bhd. It intends to explore and identify viable business opportunities. The company was founded on July 11, 2024 and is headquartered in Petaling Jaya, Malaysia.

How the Company Makes Money

Titan Pharmaceuticals generates revenue primarily through the commercialization of its flagship product, Probuphine. The company earns income from product sales, licensing agreements, and royalties. Probuphine, as a treatment for opioid dependence, is sold to healthcare providers and distributed through specialty pharmaceutical distribution channels. Additionally, Titan engages in strategic partnerships and collaborations with other pharmaceutical companies, which can result in upfront payments, milestone payments, and ongoing royalty streams based on product sales.

Black Titan Financial Statement Overview

Summary

Titan Pharmaceuticals faces significant financial challenges, marked by declining revenues, persistent losses, and negative cash flows. The company benefits from having no debt, but operational inefficiencies and diminishing asset value overshadow this advantage. Reliance on external financing is a risk, and efforts to stabilize revenue and improve profitability are crucial.

Income Statement

Titan Pharmaceuticals demonstrates a consistent decline in revenue over recent years, with the latest year showing no revenue generation. Gross profit margins have deteriorated, and the company continues to report substantial net losses, indicating ongoing challenges in achieving profitability. The negative EBIT and EBITDA margins reflect operational inefficiencies and high expenses relative to revenue.

Balance Sheet

The balance sheet shows a strong equity position with no current debt, resulting in a zero debt-to-equity ratio. However, the significant decline in total assets and stockholders' equity over time raises concerns about long-term financial health. The equity ratio remains relatively high, but the shrinking asset base could pose risks if the trend continues.

Cash Flow

Cash flow analysis indicates negative operating cash flow and free cash flow in recent years, reflecting difficulties in generating cash from operations. Although there has been a slight improvement in free cash flow year-over-year, the company is still heavily reliant on financing activities to cover its cash requirements.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-328.00	2.12M	2.08M	2.40M	1.53M	172.02K
Gross Profit	-328.00	686.84K	464.11K	550.46K	1.22M	172.02K
EBITDA	-1.67B	237.23K	107.34K	27.11K	-8.55M	-6.35M
Net Income	-1.68B	153.23K	11.69K	-86.56K	-140.37K	-297.39K
Balance Sheet
Total Assets	23.16B	23.25M	163.42K	210.72K	43.70K	284.86K
Cash, Cash Equivalents and Short-Term Investments	21.34M	156.09K	152.42K	197.72K	16.44K	41.66K
Total Debt	415.30M	0.00	0.00	0.00	395.00K	490.00K
Total Liabilities	2.62B	1.76M	35.23K	11.40K	0.00	533.29K
Stockholders Equity	20.53B	21.49M	128.19K	199.33K	0.00	-248.43K
Cash Flow
Free Cash Flow	-460.86M	-349.83K	-457.81K	-789.34K	35.84K	446.97K
Operating Cash Flow	-460.86M	-349.83K	-457.81K	-789.34K	35.84K	446.97K
Investing Cash Flow	-4.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	325.22M	353.50K	412.50K	10.12K	-61.05K	-515.90K

Black Titan Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.71
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BTTC, the sentiment is Negative. The current price of 3.71 is below the 20-day moving average (MA) of 5.49, below the 50-day MA of 5.28, and below the 200-day MA of 4.39, indicating a bearish trend. The MACD of -0.63 indicates Positive momentum. The RSI at 43.12 is Neutral, neither overbought nor oversold. The STOCH value of 2.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BTTC.

Black Titan Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
ATON	―	$32.63M	―	―	―	―	―
BCG	―	$29.55M	-15.84	-11.08%	―	-27.89%	51.00%
CWD	―	$16.05M	-0.18	―	―	-54.32%	-35.99%
BTTC	―	$4.94M	-1.25	-82.72%	―	-100.00%	54.46%
BENF	―	$8.25M	-0.08	―	―	-21.73%	98.07%